Myotonic Dystrophy Type 1

Dyne Therapeutics Advances Z-Basivarsen Toward Phase 3 in DM1

WALTHAM, Massachusetts — September 8, 2026 Dyne Therapeutics announced plans to present additional one-year clinical data from the Phase...

By cGxPwire Editor
September 9, 2026

.Clinical

Novartis Reports Phase III HARBOR Setback for Del-desiran

BASEL — September 8, 2026 Novartis announced that its global Phase III HARBOR study of delpacibart etedesiran (del-desiran) in...

By cGxPwire Editor
September 8, 2026

Bio-Pharma

Candel Therapeutics Announces Extended Phase 3 Data Presentation at ASTRO 2026

NEEDHAM, Mass., Aug. 3, 2026 Candel Therapeutics, Inc. announced that new data from its Phase 3 clinical program evaluating...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline

CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...

By cGxPwire Editor
August 4, 2026

Bio-Pharma

ARTHEx Biotech Reports ATX-01 DM1 Brain Therapy Progress

VALENCIA, Spain, July 23, 2026 ARTHEx Biotech has announced the publication of groundbreaking preclinical data demonstrating that its investigational...